OBJECTIVE: To assess the likelihood of histologic persistence/progression of complex hyperplasia and atypical hyperplasia among women treated with progestin compared with those not treated, with attention to type, dose, and duration. METHODS: This was a cohort study at an integrated health plan of women, ages 18-85 years, with complex or atypical hyperplasia on independent pathology review with a second endometrial specimen in the 2-6 months after the index diagnosis. Progestin therapy between index diagnosis and follow-up biopsy was determined from the pharmacy database. Medical record abstraction was performed. Relative risks (RRs), adjusted for age and body mass index, were calculated. RESULTS: Among 185 women, average age 55.9 years, follow-up 16.1 weeks, 115 had complex and 70 had atypical hyperplasia. Among women with complex hyperplasia, 28.4% of those treated with progestin and 30.0% of those not treated had persistence/progression (RR 1.20, 95% confidence interval [CI] 0.53-2.72). Among women with atypical hyperplasia, 26.9% of those treated with progestin and 66.7% of those not treated had persistence/progression (RR 0.39, 95% CI 0.21-0.70); there was a suggestion that use of at least a medium dose, or a duration of at least 3 months, was associated with a particularly low probability of persistence/progression. CONCLUSION: Although progestin treatment of women with atypical hyperplasia was associated with a substantial increase in the likelihood of regression of the lesion during the ensuing 2-6 months, persistence/progression was nonetheless present in more than one quarter of treated women. Regression of complex hyperplasia without atypia was common whether progestin had or had not been used.
OBJECTIVE: To assess the likelihood of histologic persistence/progression of complex hyperplasia and atypical hyperplasia among women treated with progestin compared with those not treated, with attention to type, dose, and duration. METHODS: This was a cohort study at an integrated health plan of women, ages 18-85 years, with complex or atypical hyperplasia on independent pathology review with a second endometrial specimen in the 2-6 months after the index diagnosis. Progestin therapy between index diagnosis and follow-up biopsy was determined from the pharmacy database. Medical record abstraction was performed. Relative risks (RRs), adjusted for age and body mass index, were calculated. RESULTS: Among 185 women, average age 55.9 years, follow-up 16.1 weeks, 115 had complex and 70 had atypical hyperplasia. Among women with complex hyperplasia, 28.4% of those treated with progestin and 30.0% of those not treated had persistence/progression (RR 1.20, 95% confidence interval [CI] 0.53-2.72). Among women with atypical hyperplasia, 26.9% of those treated with progestin and 66.7% of those not treated had persistence/progression (RR 0.39, 95% CI 0.21-0.70); there was a suggestion that use of at least a medium dose, or a duration of at least 3 months, was associated with a particularly low probability of persistence/progression. CONCLUSION: Although progestin treatment of women with atypical hyperplasia was associated with a substantial increase in the likelihood of regression of the lesion during the ensuing 2-6 months, persistence/progression was nonetheless present in more than one quarter of treated women. Regression of complex hyperplasia without atypia was common whether progestin had or had not been used.
Authors: B G Skov; H Broholm; U Engel; M B Franzmann; A L Nielsen; A F Lauritzen; T Skov Journal: Int J Gynecol Pathol Date: 1997-01 Impact factor: 2.762
Authors: C Bergeron; F F Nogales; M Masseroli; V Abeler; P Duvillard; E Müller-Holzner; H Pickartz; M Wells Journal: Am J Surg Pathol Date: 1999-09 Impact factor: 6.394
Authors: Cornelia L Trimble; James Kauderer; Richard Zaino; Steven Silverberg; Peter C Lim; James J Burke; David Alberts; John Curtin Journal: Cancer Date: 2006-02-15 Impact factor: 6.860
Authors: Fredrick J Montz; Robert E Bristow; Alessandro Bovicelli; Rafael Tomacruz; Robert J Kurman Journal: Am J Obstet Gynecol Date: 2002-04 Impact factor: 8.661
Authors: Kristen Upson; Kimberly H Allison; Susan D Reed; Carolyn D Jordan; Katherine M Newton; Elizabeth M Swisher; Jennifer A Doherty; Rochelle L Garcia Journal: Am J Obstet Gynecol Date: 2012-05-16 Impact factor: 8.661
Authors: Kimberly H Allison; Kristen Upson; Susan D Reed; Carolyn D Jordan; Katherine M Newton; Jennifer Doherty; Elizabeth M Swisher; Rochelle L Garcia Journal: Int J Gynecol Pathol Date: 2012-03 Impact factor: 2.762
Authors: Aliyah Almomen; Sungpil Cho; Chieh-Hsiang Yang; Zhengzheng Li; Elke A Jarboe; C Matthew Peterson; Kang Moo Huh; Margit M Janát-Amsbury Journal: Pharm Res Date: 2015-01-22 Impact factor: 4.200
Authors: Heather D Kissel; Thomas G Paulson; Karen Liu; Xiaohong Li; Elizabeth Swisher; Rochelle Garcia; Carissa A Sanchez; Brian J Reid; Susan D Reed; Jennifer Anne Doherty Journal: Obstet Gynecol Int Date: 2013-10-26